BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
6/16/2025 10:38:30 AM | Browse: 323 | Download: 843
Publication Name World Journal of Clinical Pediatrics
Manuscript ID 105731
Country United States
ISSN 2219-2808 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Pediatrics
Manuscript Type Evidence Review
Article Title Role of glucagon-like peptide-1 receptor agonists in pediatric obesity and metabolic dysfunction associated steatotic liver disease
Manuscript Source Invited Manuscript
All Author List Rahiya Rehman
ORCID
Author(s) ORCID Number
Rahiya Rehman http://orcid.org/0000-0002-5338-4787
Funding Agency and Grant Number
Corresponding Author Rahiya Rehman, Assistant Professor, MD, Department of Pediatric Gastroenterology, Saint Louis University, 1465 S Grand Blvd, Saint Louis, MO 63108, United States. rahiya.rehman@health.slu.edu
Key Words Pediatrics; Obesity; Metabolic dysfunction-associated steatotic liver disease; Glucagon-like peptide-1; Glucagon like peptide
Core Tip Understanding the impact of glucagon-like peptide-1 analogs in the pediatric population is crucial, as these medications have the potential to address a significant treatment gap in childhood metabolic disorders. Their effects on weight regulation, insulin sensitivity, and liver health could offer long-term benefits, particularly in conditions such as obesity, type 2 diabetes, and metabolic dysfunction associated steatotic liver disease. Further research and clinical trials are needed to establish their safety, efficacy, and appropriate use in children.
Publish Date 2025-06-16 10:38
Citation

Rehman R. Role of glucagon-like peptide-1 receptor agonists in pediatric obesity and metabolic dysfunction associated steatotic liver disease. World J Clin Pediatr 2025; 14(3): 105731

URL https://www.wjgnet.com/2219-2808/full/v14/i3/105731.htm
DOI https://dx.doi.org/10.5409/wjcp.v14.i3.105731
Full Article (PDF) WJCP-14-105731-with-cover.pdf